Paul Tudor Jones Enanta Pharmaceuticals Inc Transaction History

Tudor Investment Corp Et Al

$15.5 Billion
Q1 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 10,405 shares of ENTA stock, worth $125,588. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,405

Holding current value

$125,588

% of portfolio

0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$10.08 - $17.46 $104,882 - $181,671	10,405 New	10,405 $181,000
Q2 2023 Aug 14, 2023	BUY	$20.68 - $39.85 $214,348 - $413,045	10,365 New	10,365 $221,000
Q3 2022 Nov 14, 2022	SELL	$48.29 - $71.27 $80,113 - $118,236	-1,659 Reduced 13.84%	10,327 $536,000
Q2 2022 Aug 15, 2022	SELL	$38.13 - $76.93 $658,428 - $1.33 Million	-17,268 Reduced 59.03%	11,986 $567,000
Q1 2022 May 16, 2022	BUY	$56.06 - $74.11 $129,386 - $171,045	2,308 Added 8.57%	29,254 $2.08 Million

Q4 2021 Feb 14, 2022	BUY	$60.19 - $97.37 $1.15 Million - $1.85 Million	19,049 Added 241.22%	26,946 $2.02 Million
Q3 2021 Nov 15, 2021	SELL	$41.02 - $58.65 $1.78 Million - $2.55 Million	-43,479 Reduced 84.63%	7,897 $449,000
Q2 2021 Aug 16, 2021	BUY	$43.76 - $53.11 $1.37 Million - $1.67 Million	31,365 Added 156.74%	51,376 $2.26 Million
Q1 2021 May 17, 2021	SELL	$41.69 - $54.95 $1 Million - $1.32 Million	-24,075 Reduced 54.61%	20,011 $987,000
Q4 2020 Feb 16, 2021	BUY	$41.16 - $47.47 $1.81 Million - $2.09 Million	44,086 New	44,086 $1.86 Million
Q3 2020 Nov 16, 2020	SELL	$43.36 - $53.53 $486,802 - $600,981	-11,227 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$46.37 - $57.58 $520,595 - $646,450	11,227 New	11,227 $564,000

Others Institutions Holding ENTA

# of Institutions

108

Shares Held

21.7M

Call Options Held

9.4K

Put Options Held

3.3K

View Full List

About ENANTA PHARMACEUTICALS INC

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $250M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

More about ENTA

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account